Literature DB >> 3926002

Galactosylceramide- and lactosylceramide-loading studies in cultured fibroblasts from normal individuals and patients with globoid cell leukodystrophy (Krabbe's disease) and GM1-gangliosidosis.

T Kobayashi, N Shinnoh, I Goto, Y Kuroiwa, M Okawauchi, G Sugihara, M Tanaka.   

Abstract

The metabolism of galactosylceramide and lactosylceramide in cultured fibroblasts was studied using the lipid-loading test. These compounds were incorporated into the fibroblasts yet only small amounts of the incorporated lipids were hydrolyzed unless additional phospholipid was mixed with the glycolipid before loading. Among phospholipids, phosphatidylserine was the most effective for incorporation and hydrolysis of the glycolipids, while phosphatidylcholine inhibited the incorporation of the glycolipids. Using filtration techniques, light scattering analyses and subcellular fractionation, the particle size of glycolipid in the culture medium was found to be critically important for the incorporation of the lipids into the cells and their transportation to the lysosomes. The particle sizes of the glycolipids were decreased by mixing with phosphatidylserine. Furthermore, the negative charge in phosphatidylserine may be necessary for the glycolipid transportation into the lysosomes. In fibroblasts from patients with globoid cell leukodystrophy, 40-50% of galactosylceramide was hydrolyzed on the 4th day of culture, a time when the control fibroblasts had hydrolyzed it about 80%. This finding is in contrast with observations made on fibroblasts with other sphingolipidoses which showed near-zero degradation in corresponding substrate-loading tests. In fibroblasts from patients with either globoid cell leukodystrophy of GM1-gangliosidosis, hydrolysis of lactosylceramide was fairly normal yet somewhat lower than control values on any day of culture, thereby indicating that, in the loading tests, lactosylceramide seems to be hydrolyzed with similar levels of enzyme activities by two distinct beta-galactosidases, galactosylceramidase and GM1-ganglioside beta-galactosidase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3926002

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  Treating glucosphingolipid disorders by chemotherapy: use of approved drugs and over-the-counter remedies.

Authors:  N S Radin
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

Review 2.  Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates.

Authors:  Jeremy D Schmahmann; Eric E Smith; Florian S Eichler; Christopher M Filley
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

3.  Additional biochemical findings in a patient and fetal sibling with a genetic defect in the sphingolipid activator protein (SAP) precursor, prosaposin. Evidence for a deficiency in SAP-1 and for a normal lysosomal neuraminidase.

Authors:  B C Paton; B Schmid; B Kustermann-Kuhn; A Poulos; K Harzer
Journal:  Biochem J       Date:  1992-07-15       Impact factor: 3.857

4.  Metabolism of exogenous galactosylceramide in the twitcher mouse brain.

Authors:  K Mitsuo; T Kobayashi; N Shinnoh; I Goto
Journal:  Neurochem Res       Date:  1989-12       Impact factor: 3.996

5.  Involvement of very long fatty acid-containing lactosylceramide in lactosylceramide-mediated superoxide generation and migration in neutrophils.

Authors:  Kazuhisa Iwabuchi; Alessandro Prinetti; Sandro Sonnino; Laura Mauri; Toshihide Kobayashi; Kumiko Ishii; Naoko Kaga; Kimie Murayama; Hidetake Kurihara; Hitoshi Nakayama; Fumiko Yoshizaki; Kenji Takamori; Hideoki Ogawa; Isao Nagaoka
Journal:  Glycoconj J       Date:  2007-11-28       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.